Key Takeaways Overexpansion of production capacity and slow commercial uptake risk suppressing profitability and pressuring margins over multiple years. Vulnerability to global protectionism, supply chain dependence, and slow innovation in advanced drug segments threaten long-term growth and financial stability.Read more
Key Takeaways Expansion in high-demand injectables and complex generics is improving revenue mix, pricing power, and profit margins. Strategic operational shifts, global collaboration, and regulatory compliance are enhancing earnings stability and positioning the company as a preferred manufacturing partner.Read more
Key Takeaways Aggressive capacity expansion, complex product launches, and industry trends could fuel outsized revenue and earnings growth well above market expectations. Diversification into emerging markets and advanced manufacturing formats enhances earnings stability and reduces dependency on any single region or segment.Read more
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
